Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.49 |
| ▸ | ALPI | P09923 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | XIAP | P98170 | 1/20 | 0.49 |
| ▸ | PTPRC | P08575 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1827246 | 1.00 | SLC7A5 (0.50) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL19472012 | 0.84 | SLC7A5 (0.51) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL27709789 | 0.83 | SLC7A5 (0.67) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL11133474 | 0.83 | SLC7A5 (0.65) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL30202342 | 0.82 | SLC7A5 (0.51) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL28813646 | 0.80 | SLC7A5 (0.61) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL28632899 | 0.80 | SLC7A5 (0.65) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL29746697 | 0.78 | SLC7A5 (0.48) | SLC7A5PTGS1ALPIPKMXIAP | |
| Iodide SCHEMBL28632896 | 0.78 | PTPN1 (0.48) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL524638 | 0.78 | ITGB3 (0.59) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1163262-B1 | PHENYLALANINE DERIVATIVES | US GOV HEALTH & HUMAN SERV (US) | 2011-05-11 | — | — | EP | disclosed |
| US-7825216-B2 | Conjugate which inhibits SH2 domains from binding with phosphoproteins for use in prevention and/or treatment of cancer, diabetes, obesity, autoimmune, inflammatory, metabolic and/or cardiovascular diseases; pharmacokinetics, bioavailability | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-11-02 | — | — | US | disclosed |
| US-20070219194-A1 | Conjugate which inhibits SH2 domains from binding with phosphoproteins for use in prevention and/or treatment of cancer, diabetes, obesity, autoimmune, inflammatory, metabolic and/or cardiovascular diseases; pharmacokinetics, bioavailability | GEORGETOWN UNIVERSITY (US) | 2007-09-20 | — | — | US | disclosed |
| US-7226991-B1 | inhibiting SH2 domain binding with a phosphoprotein; to inhibit proliferation of tumor cells; for inhibiting the growth of human breast cancer cells | UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2007-06-05 | — | — | US | disclosed |
| EP-1163262-A1 | PHENYLALANINE DERIVATIVES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY of the DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000056760-A1 | PHENYLALANINE DERIVATIVES | THE UNITED STATES OF AMERICA, REPRESENTED BY SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219194-A1 | Conjugate which inhibits SH2 domains from binding with phosphoproteins for use in prevention and/or treatment of cancer, diabetes, obesity, autoimmune, inflammatory, metabolic and/or cardiovascular diseases; pharmacokinetics, bioavailability | TYRO3, PTMS, ACP1 | SLC7A5 124/4885PTGS1 3255/4885ALPI 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.